Boston Institute of Biotechnology, LLC’s Post

We are thrilled to be featured in Frost & Sullivan's latest article, spotlighting our leadership in the fourth wave of biologics manufacturing with the world’s first 30,000-liter ultra-large production platform. Key Highlights: -> Massive Scale Production: Leveraging 30,000-liter bioreactors, reaching a total capacity of one million liters. -> Innovative Technology: Our PanFlex® system is redefining ultra-large-scale mammalian cell production. -> Cutting-Edge Facilities: Our state-of-the-art biopharmaceutical production base is nearing completion, placing us at the forefront of industrial transformation. 💡 Why It Matters: This revolution enables more efficient, large-scale biologics production, making life-saving therapies more accessible and affordable for patients globally. As biologics demand soars, our innovative approach will address capacity shortages and drive the industry forward. Join us on this incredible journey towards a healthier future! 📖 Read the full article here: https://lnkd.in/eVCW-eSj

💼💉 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 𝗖𝗗𝗠𝗢 𝗠𝗮𝗿𝗸𝗲𝘁: 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝗶𝗻𝗴 𝗳𝗼𝗿 𝗘𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲 𝗶𝗻 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴! 🌐 This growth is fueled by: Increasing Demand for Biologics: The growing prevalence of chronic diseases, along with the development of innovative biologics and biosimilars, drives the demand for outsourced biopharmaceutical manufacturing services. 🔬 Complexity of Biologics Manufacturing: Biologics production involves intricate processes and specialized technologies, leading pharmaceutical companies to rely on CDMOs with expertise in bioprocessing, cell culture, and downstream purification. 🔗 𝗔𝗰𝗰𝗲𝘀𝘀 𝘁𝗵𝗲 𝗥𝗲𝗽𝗼𝗿𝘁: https://bit.ly/3UHJCFD 🌍 Key Players: Lonza,Catalent Pharma Solutions.,Samsung Biologics,Eurofins Scientific Finland Oy, Boehringer Ingelheim ,FUJIFILM Diosynth Biotechnologies.,WuXi Biologics, Labcorp Drug Developement.,Cambrex, AGC Biologics Emerging Players: LOTTE BIOLOGICS,Just - Evotec Biologics,Suzhou Inovance Technology Porton Biopharma Ltd,Prestige Biologics - CDMO,Chime Biologics STC Biologics Inc,BD Samsung BioLogics,Grep Technology Partners (GTP) 📌 #BiologicsCDMO #Biopharmaceuticals #ContractManufacturing #PharmaceuticalIndustry #MarketTrends #Innovation #HealthcareResearch #prophecymarketinsigts

New Innovations and outlook in Bio Pharmaceutical. Read the blog post and see you in Boston for the ISPE Bio Manufacturing Conference in June. As always yours Richard Denk SKAN

Over the past two decades, the landscape of biopharmaceuticals in the UK has undergone a significant transformation. Once a close second to the US in biopharmaceutical prominence, the UK faced a challenge in the late 1990s of converting its robust research and development (R&D) capabilities into sufficient biomanufacturing capacity. Government concerns centered on retaining skilled talent, nurturing innovative companies, and bridging the gap between research and commercial success. In the latest BioIndustry Association (BIA) blog, Julie Anderson, Head of RNA Centre of Excellence at CPI, explores the UK's biopharmaceutical journey and delves into the exciting opportunities that lie ahead. Read more: https://lnkd.in/e9fTPeZs #Biopharma #Pharma #Bioprocessing #LifeScience #Future

Outsourcing has become a pivotal strategy in the biopharmaceutical industry. Over the past two decades, reliance on Contract Development and Manufacturing Organizations (CDMOs) has grown significantly. But why has this shift occurred? Erica Friedman, Senior Research Analyst at BioPlan Associates, Inc. Associates, delves deep into the reasons, trends, and the future of outsourcing in her latest article. From the impact of COVID-19 to the rise of biologics and the global expansion of CDMOs, get a comprehensive insight into the industry's transformation. #outsourcing #biopharma #pharmaceuticals #drugdevelopment #CDMO #lifesciences

Syngene International Limited has announced the upcoming launch of their newly upgraded biologics facility, set to go operational for clinical and commercial supply in the latter half of 2024. Solutions for biotech and pharma companies seeking CDMO services for both drug substance and drug product. Here's a rundown of the features of this facility: Expanded Drug Substance Capacity With two production suites housing five 2,000-liter single-use bioreactors each, the facility boasts a substantial total capacity of 20,000 liters for drug substance manufacturing. Advanced Vial Filling Capability Equipped with two high-speed vial filling lines, the facility can churn out an astonishing 1 million vials per day, accommodating a range of fill volumes from 1 to 100 milliliters. Dedicated Development Suite A specialised development suite, complete with a 500-liter single-use bioreactor, is in place to cater to clinical supply requirements, ensuring flexibility and efficiency in meeting diverse client needs. Tripling Bio Manufacturing Capacity This expansion triples Syngene's bio manufacturing capacity, enhancing their standing as a key player in the industry. It complements their existing commercial manufacturing site, BMP 1, located in Bangalore, India, which has garnered approvals from regulatory bodies such as the US FDA and EMA. Read more in the press release below 👇 #cdmo #pharmaceuticalmanufacturing

In this article, Jinhyeok Jeong and John Thomas, Senior Directors of DP Inspection & Packaging and DP MSAT, Samsung Biologics explores the major areas of DP manufacturing that can accelerate timelines from development to commercialisation, along with the necessary qualities that should be sought after in a specialist service-providing partner. #pharma #manufacturing #commercialisation

Don't miss Kevin's insightful take on #CDMO outsourcing at Samsung Biologics! Strategic outsourcing can be a game-changer for biopharma to reduce risks, get to market faster, and open more internal bandwidth to promote your products. Hats off to the entire Samsung Biologics team for leading the way in innovation. Let's continue shaping the future of biotech together! Current and prospective clients, we'd love to hear your thoughts! How do you envision CDMO outsourcing benefiting your project endeavors? Share your insights below! 👇

As blockbuster biologic patents expire, the biosimilar market is growing, driving originator companies to redevelop their biologic products.  Turning to patient-centric methods of delivery to maintain market exclusivity, nasal and inhaled biologics are on the rise. However, a number of challenges need to be overcome for effective development of nasal and inhaled biologics.   Read more in our recent article with European Pharmaceutical Manufacturer, where our Head of Drug Product Development Ross Errington explores nasal and inhaled biologics in more detail, focusing on innovation that is making these delivery methods a possibility. Read the article in full here: https://lnkd.in/dR3f5DY9